- Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions - http://eyedocnews.com -

Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute Join Forces

Posted By Dr. Risa Schulman On June 15, 2011 @ 12:10 pm In Industry News | Comments Disabled

“It is a bad day for blindness,” said the Chairman of Massachusetts Eye and Ear’s Board of Directors Wycliffe “Wyc” Grousbec in describing the union of the Massachusetts Eye and Ear Infirmary, an academic medical center, and Schepens Eye Research Institute, an independent ophthalmology research center.  Both centers are teaching affiliates of Harvard Medical School and will be located together on a downtown Boston campus.  Schepens Eye Research Institute will become part of Mass Eye and Ear but will keep its name and non-profit status.

The alliance will combine the strong research programs in retina, glaucoma and genomics at Mass. Eye and Ear, with the expertise in ocular surface disease, immunology, stem cell therapies, regeneration, and mobility rehabilitation of Schepens Eye Research Institute.

President and COO of Schepens Eye Research Institute, Kenneth Fischer, states that in coming together, the two groups will be able to attract the highest level new and veteran researchers as well as improve their attractiveness for federal and industry funding.

“This creates a powerhouse in vision research that we are confident will accelerate the eradication of blinding diseases,” said Grousbec.

For a press release on the event, click here [1].

Risa Schulman, PhD
Expert, Healthy Food and Dietary Supplement Science, Marketing and Regulatory

Article printed from Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions: http://eyedocnews.com

URL to article: http://eyedocnews.com/005534-two-powerhouses-in-eye-research-join-forces/

URLs in this post:

[1] here: http://www.schepens.harvard.edu/press_releases/june_9_2011.html

Copyright © 2008 Eye Doc Talk. All rights reserved.